Gold prices slip after rallying on Powell rate cut talk
On Wednesday, Evercore ISI analysts adjusted their outlook on Cytokinetics (NASDAQ:CYTK), reducing the price target to $60 from $65, while maintaining an Outperform rating on the stock. The adjustment comes as the company’s shares have declined over 20% in the past week, now trading near its 52-week low of $32.74. According to InvestingPro data, analyst price targets for CYTK currently range from $41 to $120, suggesting significant potential upside. The revision follows a detailed assessment of the company’s recent challenges with the REMS process for its product aficamten, as well as updates to the ACACIA trial design.
The analysts acknowledged that Cytokinetics took a risk with the REMS strategy that did not yield the desired outcome, noting that while the decision can be debated, the focus should remain on the strong data supporting aficamten’s approval and market potential. Despite the setback, the analysts remain optimistic about the drug’s prospects. InvestingPro analysis shows the company maintains strong financial flexibility with a current ratio of 6.17, indicating ample liquidity to fund its development pipeline.
Cytokinetics faced pressure from European and Japanese regulators, which led to changes in the ACACIA trial design for treating hypertrophic cardiomyopathy (nHCM). The analysts have incorporated these updates into their financial model, slightly delaying the expected launch of aficamten to account for the new Prescription Drug User Fee Act (PDUFA) date set for December 26, 2025.
In their commentary, the analysts stated, "After being asked the same question in every way imaginable, our high-level takeaway on the REMS ordeal is that CYTK took a risk that ultimately did not pay off. We can debate whether or not that was a shot worth taking, but hindsight is 20/20. At the end of the day, we still expect aficamten’s strong data package to warrant approval and position it well in the market. Separately, ACACIA’s (nHCM) trial design updates appear benign with CYTK indicating pressure from EU/Japanese regulators led to the changes. We’ve updated our model based off the latest Q & slightly pushed afi’s launch to reflect the new 12/26/25 PDUFA. Reit OP, PT to $60."
The revised price target reflects the latest developments and expectations for Cytokinetics’ product pipeline, with a continued positive outlook on the company’s performance in the market despite recent regulatory challenges. While the company posted impressive revenue growth of 145% in the last twelve months, InvestingPro subscribers have access to over 10 additional key insights and a comprehensive Pro Research Report that provides deeper analysis of CYTK’s financial health and market position.
In other recent news, Cytokinetics reported its financial results for the first quarter of 2025, revealing a net loss of $161.4 million, or $1.36 per share. The company’s revenue was $1.6 million, which fell short of the $3.6 million forecast. Despite this revenue miss, the earnings per share slightly exceeded expectations, coming in marginally better than the forecasted loss of $1.37 per share. Meanwhile, Cytokinetics is navigating a regulatory delay, as the FDA extended the Prescription Drug User Fee Act (PDUFA) date for its drug candidate aficamten by three months to December 26, 2025. This extension allows the FDA more time to review the New Drug Application (NDA), which was submitted without a Risk Evaluation and Mitigation Strategy (REMS) plan.
Citi analysts have adjusted their stance on Cytokinetics, reducing the stock’s price target from $86.00 to $80.00, while maintaining a Buy rating. The analysts interpret the company’s decision to submit the NDA without a REMS as a strategic move to secure approval without stringent constraints. JMP Securities also maintained a positive outlook on Cytokinetics, reiterating a Market Outperform rating with a $78.00 price target. They anticipate that aficamten will receive FDA approval with a differentiated REMS, potentially allowing for less stringent monitoring compared to competitors.
Furthermore, Cytokinetics announced accelerated enrollment in the Phase 3 ACACIA trial for aficamten in non-hypertrophic cardiomyopathy (nHCM), potentially shortening the timeline by six months. With Camzyos no longer in development for nHCM, a positive outcome from the ACACIA trial in the first half of 2026 could significantly benefit the company. Despite the challenges, Cytokinetics remains focused on advancing its pipeline and preparing for potential product launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.